2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1491

Oestrogen Levels and the Outcome of Leflunomide Treatment in Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1099

Ongoing DNA Damage, Chromatin Deregulation and Defective DNA Damage Response in Systemic Autoimmune Rheumatic Diseases

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1302

Opioid Analgesic Use in Acute Gout Patients Discharged from the Hospital

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1049

Optical Biomarkers for the Early Diagnosis of Osteoarthritis

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1444

Optimization of Ultrasonographic Examination for the Diagnosis of Erosive Rheumatoid Arthritis Versus Erosive Osteoarthritis with Radiography Considered As Gold Standard

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1804

Optimization Protocol for Adalimumab Treatment in Refractory Uveitis Due to Behçet’s Disease

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1031

Orally Administered Cherry Juice Inhibits Localized Nfκb Activity and Histopathological Infiltrates in a Murine Model of Gout

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 1301

Organic Anion Transport Inhibitors Suppress Chondrocyte Pyrophosphate Production

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1239

Organisms Associated with Prosthetic Joint Septic Arthritis over the Past Two Decades: Data from a Single Tertiary Medical Center Located in the Northeastern United States

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1523

Pain Is Improved in Around 50% of Patients and Fatigue in 40% of Patients with Rheumatoid Arthritis Treated with Sarilumab in the Target, Mobility and Monarch Trials

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1428

Parental Involvement and Adolescents/Young Adults Self-Management during the Transition Period: A Cross-Sectional Survey in Childhood Onset Rheumatic Diseases

Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

9:00AM-11:00AM: Abstract Number: 1030

Parenteral Injection of Human Adipose-Derived Mesenchymal Stem Cells Attenuates Inflammation in an Acute Model of Gouty Arthritis

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 1587

Pathogenic Role of Interleukin 27 in the Nonobese Diabetic Mouse Model of Sjögren Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1519

Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1391

Patient-Acceptable Symptom State in Psoriatic Arthritis: Prevalence and Associated Factors in Real Clinical Practice

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].